文献速递慢性肾脏病

靶向炎症治疗糖尿病肾病:通往2030之路

Targeting inflammation to treat diabetic kidney disease: the road to 2030.
PubMed 文献 · Kidney Int · 2022-12-05

糖尿病肾病(DKD)是慢性肾脏病增长最快的原因之一;临床前研究显示炎症参与其发病和肾脏损伤进展。钠-葡萄糖协同转运蛋白2抑制剂和非奈利酮的成功改变了指南和标准治疗,使直接靶向炎症介质的旧研究过时,多数抗炎药物的临床开发于2016年终止。本文综述当前标准治疗、在研疗法或老药新用对肾脏炎症的影响,总结DKD炎症分子调控进展并讨论具有临床相关性的潜在新策略,最后提出将炎症与DKD知识整合到临床实践的未来研究路线图。

要点

  • 糖尿病肾病是慢性肾脏病增长最快的原因之一,炎症参与其发病和肾脏损伤进展。
  • 钠-葡萄糖协同转运蛋白2抑制剂和非奈利酮改变了指南和标准治疗,使直接靶向炎症介质的旧研究过时。
  • 本文综述现有治疗和在研疗法对肾脏炎症的影响,并提出未来研究路线图。

核心结论

  • 鉴于炎症对DKD发病的贡献,本文综述当前标准治疗、在研疗法或老药新用对肾脏炎症的影响,总结DKD炎症分子调控进展并讨论潜在新治疗策略,最后提出将炎症与DKD知识整合到临床实践的未来研究路线图。

研究设计与样本

  • 综述,检索范围未在原文明确报告。

主要发现

  • 临床前研究显示炎症参与DKD发病和肾脏损伤进展。
  • 钠-葡萄糖协同转运蛋白2抑制剂和非奈利酮的成功改变了指南和标准治疗,使直接靶向炎症介质的旧研究过时,多数抗炎药物在DKD的临床开发于2016年终止。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney disease and associated morbidity and mortality. Preclinical research has demonstrated the involvement of inflammation in its pathogenesis and in the progression of kidney damage, supporting clinical trials designed to explore anti-inflammatory strategies. However, the recent success of sodium-glucose cotransporter-2 inhibitors and the nonsteroidal mineralocorticoid receptor antagonist finerenone has changed both guidelines and standard of care, rendering obsolete older studies directly targeting inflammatory mediators and the clinical development was discontinued for most anti-inflammatory drugs undergoing clinical trials for DKD in 2016. Given the contribution of inflammation to the pathogenesis of DKD, we review the impact on kidney inflammation of the current standard of care, therapies undergoing clinical trials, or repositioned drugs for DKD. Moreover, we review recent advances in the molecular regulation of inflammation in DKD and discuss potential novel therapeutic strategies with clinical relevance. Finally, we provide a road map for future research aimed at integrating the growing knowledge on inflammation and DKD into clinical practice to foster improvement of patient outcomes.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022. PMID: 36470394. doi:10.1016/j.kint.2022.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。